hypertension%20in%20pregnancy
HYPERTENSION IN PREGNANCY
Hypertension in pregnancy is defined as an average diastolic blood pressure of ≥90 mmHg, based on at least 2 measurements, ≥4 hours apart or systolic blood pressure of ≥140 mmHg taken at least 6 hours apart.
Diagnosis of severe hypertension is made when blood pressure is ≥160/110 mmHg.
Measurement should be repeated after 15 minutes for confirmation.

Diagnosis

Preeclampsia/Eclampsia

  • Always presents potential danger to the mother and baby; therefore, prevention relies on identifying high-risk women
    • Close clinical and lab monitoring aimed at early recognition and institution of monitoring or delivery when indicated

Evaluation

Clinical Blood Pressure (BP) Measurement
  • Patient should be seated quietly for at least 5 minutes in a chair with feet on the floor and arm supported at heart level prior to measurement of BP
  • Appropriately-sized cuff should be placed at heart level of the patient and should not be placed over any clothing
  • Use the appearance of phase I Korotkoff’s sounds for systolic blood pressure (SBP) and the disappearance of phase V for diastolic blood pressure (DBP)
  • Differences of BP between 2 arms should be noted, and the arm with consistently higher measurement should be used for all subsequent BP readings
Confirmation of Elevated BP
  • Diagnosis of hypertension is based on office or in-hospital BP measurements
  • Hypertension in pregnancy is defined as an average DBP of ≥90 mmHg, based on at least 2 measurements, ≥4 hours apart or SBP ≥140 mmHg taken at least 6 hours apart
  • Diagnosis of severe hypertension is made when BP is ≥160/110 mmHg
    • Measurement should be repeated after 15 minutes for confirmation
Findings that Support the Diagnosis of Severe Preeclampsia
One or more of the following:
  • SBP ≥160 mmHg and/or DBP ≥110 mmHg on 2 occasions at least 4 hours apart during bed rest
  • Platelet <100,000 cells/mm3 or microangiopathic hemolytic anemia (with increased lactic acid dehydrogenase)
  • Elevated liver enzymes [aspartate aminotransferase (AST) or alanine aminotransferase (ALT)]
  • Persistent headache or other cerebral or visual disturbances
  • Persistent epigastric or right upper quadrant pain
  • Pulmonary edema and/or congestive heart failure
  • Severe proteinuria  and oliguria <500 mL/day
  • Serum creatinine >1.1 mg/dL or increased to twice the normal concentration without other renal disease
  • HELLP syndrome (hemolysis, elevated liver enzymes, low platelet count)

Assessment

Risk Stratification
  • Decisions on the management of hypertension should be based on blood pressure (BP) levels along with other cardiovascular (CV) risk factors, target organ damage (TOD) and concomitant disorders
Low-Risk Hypertension
  • SBP 140-179 mmHg or DBP 90-110 mmHg
  • Normal physical exam
  • Normal echocardiography (ECG) and echo
  • Without proteinuria
High-Risk Hypertension
  • SBP ≥180 mmHg or DBP ≥110 mmHg
  • End-organ involvement
  • Poor obstetric history, comorbidity with renal impairment, diabetes mellitus (DM) or collagen vascular diseases
Work-up for Chronic Hypertension
  • Evaluate patients with preexisting hypertension before pregnancy to define its severity and to facilitate planning for changes in lifestyle and pharmacotherapy if required
  • If a woman’s BP elevation is confirmed and especially if it is severe, a woman should be evaluated for potentially reversible causes
  • Woman with a history of high BP for several years should be evaluated for TOD

Laboratory Tests

 Lab Tests for Chronic Hypertension

  • Should be taken, if not yet done previously or recently, to exclude secondary causes, risk factors and TOD
    • Complete blood count (CBC), urinalysis, renal function test, fasting blood sugar, lipid profile (after 9- to 12-hour fast), serum sodium (Na), potassium (K), uric acid
    • Chest X-ray
    • 12-lead echocardiography (ECG)
Presence of Secondary Cause or Evidence of Target Organ Damage (TOD)
  • Patient should be referred to a specialist and treated appropriately if a secondary cause of hypertension is found
  • Further tests should be done, if TOD is found, in order to evaluate the level of severity
Pregnancy Assessment

Check for Proteinuria
  • All pregnant women should be checked for proteinuria
    • 24-hour urine collection is recommended but other acceptable methods are urine dipstick test or urine protein: creatinine ratio
    • Proteinuria should be suspected in patients with ≥2+ protein on urine dipstick
    • Confirmation of proteinuria: ≥300 mg/day in a 24-hour urine sample or ≥30 mg/mmol urine creatinine in a random urine sample
Other Lab Tests
  • It is important to rule out preeclampsia in pregnant women with hypertension
  • The following are used to distinguish preeclampsia from chronic hypertension: CBC, platelet count, blood smear, coagulation profile, serum creatinine, uric acid, liver enzymes, serum albumin, lactic acid dehydrogenase
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 05 Dec 2017
Discontinuation of aspirin may have detrimental consequences for long-term users, with a recent study reporting that cessation of use in the absence of major surgery or bleeding increases the risk of cardiovascular events.
19 Dec 2016
The prevalence of ECG for left ventricular hypertrophy (LVH) may vary depending on the criteria used across body mass index (BMI) categories in a low cardiovascular risk cohort, suggests a new study.
02 Dec 2017
The risk of congenital heart disease (CHD) Is significantly higher in foetuses conceived through in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI), according to a recent study.
Pearl Toh, 2 days ago
A higher dose of pitavastatin can benefit Japanese patients with stable coronary artery disease (CAD) compared with a low-dose pitavastatin, even though cardiovascular (CV) event incidence is known to be lower in Asian than Western patients, according to the REAL-CAD study presented at the AHA Scientific Sessions 2017.